Abstract:Background Recent data in esophageal cancer suggests the variant allele of a single-nucleotide polymorphism (SNP) in XRCC1 may be associated with resistance to radiochemotherapy. However, this SNP has not been assessed in a histologically homogeneous clinical trial cohort that has been treated with a uniform approach. In addition, whether germline DNA may serve as a surrogate for tumor genotype at this locus is unknown in this disease. Our objective was to assess this SNP in relation to the pathologic complete response (pCR) rate in subjects with esophageal adenocarcinoma who received cisplatin-based preoperative radiochemotherapy in a multicenter clinical trial (Eastern Cooperative Oncology Group 1201). As a secondary aim, we investigated the rate of allelic imbalance between germline and tumor DNA. Methods Eighty-one eligible treatment-naïve subjects with newly diagnosed resectable esophageal adenocarcinoma received radiotherapy (45 Gy) concurrent with cisplatin-based chemotherapy, with planned subsequent surgical resection. The primary endpoint was pCR, defined as complete absence of tumor in the surgical specimen after radiochemotherapy. Using germline DNA from 60 subjects, we examined the base-excision repair SNP, XRCC1 Arg399Gln, and 4 other SNPs in nucleotide excision ( XPD Lys751Gln and Asp312Asn, ERCC1 3' flank) and double-stranded break ( XRCC2 5' flank) repair pathways, and correlated genotype with pCR rate. Paired tumor tissue was used to estimate the frequency of allelic imbalance at the XRCC1 SNP. Results The variant allele of the XRCC1 SNP (399Gln) was detected in 52% of subjects. Only 6% of subjects with the variant allele experienced a pCR, compared to 28% of subjects without the variant allele (odds ratio 5.37 for failing to achieve pCR, p = 0.062). Allelic imbalance at this locus was found in only 10% of informative subjects, suggesting that germline genotype may reflect tumor genotype at this locus. No significant association with pCR was noted for other SNPs. Conclusions Assessed for the first time in a prospective, interventional trial cohort of esophageal adenocarcinoma, XRCC1 399Gln was associated with resistance to radiochemotherapy. Further investigation of this genetic variation is warranted in larger cohorts. In addition, these data indicate that germline genotype may serve as a surrogate for tumor genotype at this locus.

Use Of Genetic Variations To Predict Toxicity Associated With Neoadjuvant Chemoradiation For Ajcc Stage Ii/Iii Rectal Cancer.

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Gene Polymorphisms Predict Toxicity to Neoadjuvant Therapy in Patients with Rectal Cancer

Use of the XRCC1 Single Nucleotide Polymorphism to Predict Pathologic Complete Response to Neoadjuvant Chemoradiation in Stage II/III Rectal Cancer.

Genetic Polymorphisms in Genes Regulating Cell Death and Prognosis of Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

DNA Repair Gene Polymorphisms Do Not Predict Response to Radiotherapy-Based Multimodality Treatment of Patients with Rectal Cancer: a Meta-Analysis.

Lack of Correlation Between ERCC1 (C8092A) Single Nucleotide Polymorphism and Efficacy/toxicity of Platinum Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

Associations of Genetic Variations in Mismatch Repair Genes MSH3 and PMS1 with Acute Adverse Events and Survival in Patients with Rectal Cancer Receiving Postoperative Chemoradiotherapy.

Genetic Variation in DNA-repair Pathways and Response to Radiochemotherapy in Esophageal Adenocarcinoma: a Retrospective Cohort Study of the Eastern Cooperative Oncology Group

Effect of Polymorphisms in Xpd on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients

Identification of a Biomarker Profile Associated with Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer.

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer

Relationship between Polymorphism of X-ray Repair Cross-complementing Group 1(XRCC1)Genes and Clinical Outcome of Advanced Gastric Cancer Patients Treated with DDP-based Chemotherapy

Use of Kras Codon 13 Mutations to Predict Response to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma.

Genetic Polymorphisms Of Ercc1-118, Xrcc1-399 And Gstp1-105 Are Associated With The Clinical Outcome Of Gastric Cancer Patients Receiving Oxaliplatin-Based Adjuvant Chemotherapy

Associations of Genetic Variations in MicroRNA Seed Regions With Acute Adverse Events and Survival in Patients With Rectal Cancer Receiving Postoperative Chemoradiation Therapy.

Genetic Polymorphism of ERCC1 and XRCC1 Correlated with Response to Oxaliplatin Based Chemotherapy in Advanced Colorectal Cancer

Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer